We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cardinal Health (CAH) Q4 Earnings: Disappointment in Store?
Read MoreHide Full Article
Cardinal Health Inc. (CAH - Free Report) is set to report fourth-quarter fiscal 2016 earnings results on Aug 2. Last quarter, the company reported earnings of $1.43 per share, which beat the Zacks Consensus Estimate by a dime.
Notably, Cardinal Health posted a positive earnings surprise of 9.75% on an average over the last four quarters.
Let’s see how things are shaping up for this announcement.
Factors at Play
Cardinal Health is banking on acquisitions, strategic buyouts, joint ventures and supply agreements to drive growth. The aging population presents a significant growth opportunity for the company.
However, Cardinal Health anticipates generic sales to remain sluggish in the near term. Further, generic pricing pressure remains a concern. We believe the Red Oak sourcing venture with CVS Health will help Cardinal Health to fend off this headwind.
Meanwhile, the company’s growing product volumes in the nuclear pharmacy business is a positive. Additionally, Cardinal Health’s focus on participating in the manufacture and distribution of new therapeutic radio biopharmaceuticals are expected to diversify revenues.
Moreover, the synergies from the acquisitions of Metro Medical, The Harvard Drug Group and Cordis are key catalysts. Moreover, strong growth in China (strong double-digit top and bottom-line growth in the third quarter) is predicted to drive Cardinal Health’s top-line growth.
Earnings Whispers
Our proven model does not conclusively show that Cardinal Health is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.
Zacks ESP: Cardinal Health has an Earnings ESP of -1.11%. That is because the Most Accurate estimate of $1.11 is lower than the Zacks Consensus Estimate of $1.13.
Zacks Rank: Cardinal Health carries a Zacks Rank #4 (Sell). We caution against stocks with a Zacks Rank #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some companies you may consider as our model shows they have the right combination of elements to post an earnings beat this quarter:
Nektar Therapeutics (NKTR - Free Report) with an Earnings ESP of +50.00% and Zacks Rank #1.
GlycoMimetics Inc. (GLYC - Free Report) with an Earnings ESP of +13.64% and Zacks Rank #1.
ANI Pharmaceuticals Inc. (ANIP - Free Report) with an Earnings ESP of +2.63% and a Zacks Rank #1.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cardinal Health (CAH) Q4 Earnings: Disappointment in Store?
Cardinal Health Inc. (CAH - Free Report) is set to report fourth-quarter fiscal 2016 earnings results on Aug 2. Last quarter, the company reported earnings of $1.43 per share, which beat the Zacks Consensus Estimate by a dime.
Notably, Cardinal Health posted a positive earnings surprise of 9.75% on an average over the last four quarters.
Let’s see how things are shaping up for this announcement.
Factors at Play
Cardinal Health is banking on acquisitions, strategic buyouts, joint ventures and supply agreements to drive growth. The aging population presents a significant growth opportunity for the company.
CARDINAL HEALTH Price and EPS Surprise
CARDINAL HEALTH Price and EPS Surprise | CARDINAL HEALTH Quote
However, Cardinal Health anticipates generic sales to remain sluggish in the near term. Further, generic pricing pressure remains a concern. We believe the Red Oak sourcing venture with CVS Health will help Cardinal Health to fend off this headwind.
Meanwhile, the company’s growing product volumes in the nuclear pharmacy business is a positive. Additionally, Cardinal Health’s focus on participating in the manufacture and distribution of new therapeutic radio biopharmaceuticals are expected to diversify revenues.
Moreover, the synergies from the acquisitions of Metro Medical, The Harvard Drug Group and Cordis are key catalysts. Moreover, strong growth in China (strong double-digit top and bottom-line growth in the third quarter) is predicted to drive Cardinal Health’s top-line growth.
Earnings Whispers
Our proven model does not conclusively show that Cardinal Health is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.
Zacks ESP: Cardinal Health has an Earnings ESP of -1.11%. That is because the Most Accurate estimate of $1.11 is lower than the Zacks Consensus Estimate of $1.13.
Zacks Rank: Cardinal Health carries a Zacks Rank #4 (Sell). We caution against stocks with a Zacks Rank #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some companies you may consider as our model shows they have the right combination of elements to post an earnings beat this quarter:
Nektar Therapeutics (NKTR - Free Report) with an Earnings ESP of +50.00% and Zacks Rank #1.
GlycoMimetics Inc. (GLYC - Free Report) with an Earnings ESP of +13.64% and Zacks Rank #1.
ANI Pharmaceuticals Inc. (ANIP - Free Report) with an Earnings ESP of +2.63% and a Zacks Rank #1.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>